Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone/metformin versus sitagliptin/metformin fixed-dose combination in adults with type 2 diabetes inadequately controlled on metformin
ChiCTR1900021861Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sitagliptin, pioglitazone and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Reduced level of glycated hemoglobin (HbA1c), Fasting insulin level and 2 more. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
sitagliptinpioglitazonemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900021861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021861.